P/B
2,4
Abeona Therapeutics
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company’s development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company’s development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
$310.2M
Market Cap • 9/11/2026
1974
(52 years)
Founded
1980
(46 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
—
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
2,2
EPS
—
Market Cap
Market Cap
310,2M
EV
239,5M
EV/Revenue
0
EV/EBITDA
-3
EV/EBIT
-2,9
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
0%
Total Yield
0%
Payout
0%
Retained Earnings
-779,3M
Profitability
Gross Margin
—
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
0%
Capex/Revenue
0%
Capex/D&A
180%
Capex/OCF
-6,7%
SBC/OCF
—
% PPE
3,6%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Op. Income 5Y
7,8%
CAGR Net Income 5Y
3%
CAGR EPS 5Y
-39,5%
CAGR OCF 5Y
15,4%
Leverage
N.D./EBITDA
0,9
Debt/Equity
0%
Current Ratio
4,3
Quick Ratio
4,1
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!